InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,246.68
(
0.48%
)
US TECH 100
17,832.80
(
0.62%
)
Dow Jones
39,558.11
(
0.32%
)
Brent Oil
82.52
(
-0.84%
)
Bitcoin
61,590.61
(
-2.09%
)
Post# of 75087
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Let's Roll

Send PM Follow Ignore
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Let's Roll

Re: None

Thursday, 03/23/2017 9:00:10 AM

Thursday, March 23, 2017 9:00:10 AM

Post# of 75087
$RGBP Regen BioPharma Inc. (RGBP), (RGBPP), has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv Inc., for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen's patented screening methodology and unique chemical libraries.

https://finance.yahoo.com/news/regen-biopharma-inc-provides-nr2f6-120000232.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up